OPTIC Primary Analysis: a Dose-Optimization Study of 3 Starting Doses of Ponatinib in CML Treatment

Now Viewing

EP: 1.OPTIC Primary Analysis: a Dose-Optimization Study of 3 Starting Doses of Ponatinib in CML Treatment

EP: 2.Phase II Results: Ponatinib + Blinatumomab in Ph+ ALL

EP: 3.GIMEMA LAL2116, D-ALBA, Updated Results and Prognostic Impact of IKZF1 in Ph+ ALL

EP: 4.GIMEMA LALl2317: Sequential Chemotherapy and Blinatumomab for Adult ALL

EP: 5.MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

Data from the following presentations are discussed:

• OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON). (Cortes, ASCO 2021 Abstract 7000)
  • Efficacy: In this phase 2 dose optimization trial, treatment or exposure to ponatinib suggested a correlation between dose level and rates of adverse events (AEs) and measurable treatment responses. An optimal benefit/risk ratio was noted at a dose of 45 mg/d (milligrams per day), with a further dose reduction to 15 mg/d when a ≤1% BCR-ABL1IS was achieved. This benefit was noted to be most pronounced in patients with a T315I mutation.
  • Safety: AEs and serious AEs were noted across all treatment cohorts, with the most commonly seen grades ≥3 TEAEs leading to treatment discontinuation being thrombocytopenia (27%), neutropenia (17%) and anemia (7%).

Sponsorship Support From Takeda. Content Independently Developed by OncLive.